Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Etonogestrel
Drug ID BADD_D00852
Description Etonogestrel molecule is a 3-ketodesogestrel or 19-nortestosterone which is a synthetic biologically active metabolite of progestin desogestrel.[A37184] The first product including etonogestrel was developed by the Merck subsidiary Organon and FDA approved in 2001.[L5692]
Indications and Usage For use as a female contraceptive (depot).
Marketing Status Prescription; Discontinued
ATC Code G03AC08
DrugBank ID DB00294
KEGG ID D04104
MeSH ID C044815
PubChem ID 6917715
TTD Drug ID D02KIU
NDC Product Code 65089-0053; 64918-1500; 60870-0475; 78206-145; 71161-147; 63190-0480; 63190-0260; 45541-1192; 64918-1906
Synonyms etonogestrel | 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one | 3-oxodesogestrel | 3-ketodesogestrel | 3-oxo desogestrel | 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-11-methylene-, (17-alpha)- | 3-keto-desogestrel | ORG-3236 | Implanon | nexplanon
Chemical Information
Molecular Formula C22H28O2
CAS Registry Number 54048-10-1
SMILES CCC12CC(=C)C3C(C1CCC2(C#C)O)CCC4=CC(=O)CCC34
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disturbance in attention19.21.02.002; 17.03.03.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.080428%
Drug hypersensitivity10.01.01.001--Not Available
Dry skin23.03.03.001--
Dysfunctional uterine bleeding21.01.01.001; 05.05.01.0030.007012%Not Available
Dyskinesia17.01.02.006--
Dysmenorrhoea21.01.01.0020.044545%
Dyspareunia21.03.02.016; 19.08.05.0040.002475%
Dyspepsia07.01.02.001--
Dysphagia07.01.06.003--
Dyspnoea22.02.01.004; 02.01.03.002--
Dysuria20.02.02.002--
Eating disorder19.09.01.008; 14.03.01.008--Not Available
Ectopic pregnancy18.02.02.0020.007837%Not Available
Eczema23.03.04.0060.003300%
Emotional disorder19.04.02.0050.016086%Not Available
Endometriosis21.07.01.0040.002475%Not Available
Endometritis21.14.01.002; 11.01.10.0050.001237%Not Available
Epilepsy17.12.03.002--Not Available
Epistaxis24.07.01.005; 22.04.03.001--
Erythema23.03.06.0010.020623%Not Available
Erythema nodosum23.07.02.001; 10.02.01.0200.000825%Not Available
Eye pain06.08.03.002--
Eye swelling06.08.03.003--Not Available
Facial pain08.01.08.0120.001650%
Fat tissue increased08.01.03.0090.002062%Not Available
Fatigue08.01.01.002--
Fear19.06.03.001--Not Available
Feeling abnormal08.01.09.0140.031759%Not Available
Feeling cold08.01.09.008--Not Available
The 4th Page    First    Pre   4 5 6 7 8    Next   Last    Total 19 Pages